Bionovo Launches Pharmacokinetics Trial Of Its Lead Menopause Drug Candidate, MF101
Sat, 20 Jan 2007 08:00 AM EST
... Bionovo, Inc. (OTC Bulletin Board: BNVI) has begun enrollment for its single ascending dose pharmacokinetics clinical trial to further evaluate the company's lead drug candidate, MF101, designed to treat the symptoms of menopause. The clinical trial will take place at the University of Colorado at Denver and Health Sciences Center, with Dr. Thomas Henthorn as lead investigator. [click link for full article] ...
Related Topics
- Clinical Trials
- Lead Poisoning
- Lead
- Menopause
- Blood Lead Levels
- Drug Safety
- Prescription Drugs
- Tarceva
- Drug Side Effects
- Premature Ovarian Failure
- Drug Abuse
- Drug Information
- Perimenopause
- Prescription Drug Abuse
- Prescription Drugs Abuse
- Poisoning
- Usher Syndrome: New Insights Lead to Earlier Treatment
- Over-the-Counter Medicines
- Insomnia
- Danazol

Not Signed In -


